Niedermolekulare Heparine

Heparin ist eine wasserlösliche polyanionische Substanz, die vor allem in Mastzellen, aber auch in basophilen Granulozyten gespeichert wird. Lunge, Leber und Darm sind besonders reichhaltig an Mastzellen und daher an Heparin.

Niedermolekulare Heparine sind ein Produkt des nativen Heparins, das, wie zahlreiche Studien der letzten Jahre gezeigt haben, natives Heparin in vielen Indikationen zumindest gleichwertig ersetzen kann. Durch die unkomplizierte Anwendung hat es auch für die ambulante Betreuung zunehmende Bedeutung erlangt.

Literatur

• 1 Weitz J I. Low-molecular-weight heparins.  NEJM. 1997;  337 688-698
• 2 Hirsh J, Anand S S, Halperin J L, Fuster V. Guide to anticoagulant therapy: Heparin.  Circulation. 2001;  103 2994-3018
• 3 De Swart C A, Nijmeyer B, Roelofs J M, Sixma J J. Kinetics of intravenously administered heparin in normal humans.  Blood. 1982;  60 1251-1258
• 4 Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells.  Thromb Res. 1978;  12 773-782
• 5 Mahadoo J, Heibert L, Jaques L B. Vascular sequestration of heparin in man.  Thromb Res. 1978;  12 79-90
• 6 Frydman A M, Bara L, Le Roux Y, Woler M, Chauliac F, Samana M M. The antithrombotic activity and pharmocokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 up to 80 mg.  J Clin Pharmacol. 1988;  28 609-618
• 7 Bradbrook I D, Magnani H N, Moelker H C. et al . ORG 10 172: a low molecular weight heparinoid anticoagulant with a long half-life in man.  Br J Clin Pharmacol. 1987;  23 667-675
• 8 Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.  NEJM. 1996;  335 696-700
• 9 Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiani M, Andrioli G C, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.  NEJM. 1998;  339 80-85
• 10 Geerts W H, Jay R M, Code K I, Chen E, Szalai J P, Saibil E A, Hamilton P A. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.  NEJM. 1996;  335 701-707
• 11 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie A G, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  NEJM. 1996;  334 677-681
• 12 Koopman M MW, Prandoni P, Piovella F, Ockelford P A, Brandjes D PM, van der Meer J, Gallus A S, Simonneau G, Chesterman C H, Prins M H, Bossuyt P MM, De Haes H, van den Belt A GM, Sagnard L, D’Azemar P, Büller H R. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  NEJM. 1996;  334 682-687
• 13 Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.  NEJM. 2001;  344 626-631
• 14 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J -P, Azarian R, Laurent M, Hirsch J -L, Ferrari E, Bosson J -L, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  NEJM. 1997;  337 663-669
• 15 Wallentin L, Ohlsson J, Swahn E. Low-molecular-weight heparin during instability in coronary artery disease.  Lancet. 1996;  347 561-568
• 16 Klein W, Buchwald A, Hillis S E, Monrad S, Sanz G, Turpie A GG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease.  Circulation. 1997;  96 61-68
• 17 Cohen M, Demers C, Gurfinkel E P, Turpie A GG, Fromell G J, Goodman S, Langer A, Califf R M, Fox K AA, Premmereur J, Bigonzi F. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease.  NEJM. 1997;  337 447-452
• 18 Antmann E M, McCabe C H, Gurfinkel E P, Turpie A GG, Bernink P JLM, Salein D, de Luna A B, Fox K, Lablanche J -M, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.  Circulation. 1999;  100 1593-1601
• 19 Yusuf S. for the Direct Thrombin Inhibitor Trialists’ Collaborative Group . Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data.  Lancet. 2002;  359 294-302
• 20 Montalescot G, Polle V, Collet J P, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low molecular weight heparin after mechanical heart valve replacement.  Circulation. 2000;  101 1083-1086
• 21 Kay R, Wong K S, Vu Y L, Chan Y W, Tsoi T H, Ahuja A T, Chan F L, Fong K Y, Law C B, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke.  NEJM. 1995;  333 1588-1593
• 22 Brott T, Bogousslavsky J. Treatment of acute ischemic stroke.  NEJM. 2000;  343 710-722
• 23 Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin.  Haemostasis. 2000;  30 243-248
• 24 Sanson B J, Lensing A W, Prins M H, Ginsberg J S, Barkagan Z S, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen J D, Boda Z, Turi S, Mac-Gillavry M R, Hamulyak K, Theunissen I M, Hunt B J, Buller H R. Safety of low-molecular-weight heparin in pregnancy: a systematic review.  hromb Haemost. 1999;  81 668-672
• 25 Malsch R, Harenberg J, Guerrini M, Torri G, Casu B, Heene D L. Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins.  Semin Thromb Hemost. 1994;  20 182-192
• 26 Warkentin T E, Levine M N, Hirsh J, Horsewood P, Roberts R S, Gent M, Kelton J G. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 27 Muir J M, Hirsh J, Weitz J I, Andrew M, Young E, Shaughnessy S G. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.  Blood. 1997;  89 3236-3242
• 28 Bhandari M, Hirsh J, Weitz J I, Young E, Venner T J, Shaughnessy S G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro.  Thromb Haemost. 1998;  80 413-417
• 29 Smith B S, Gandhi P J. Pharmacokinetics and phamacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.  J Thrombosis Thrombolysis. 2001;  11 39-48
• 30 Turpie A GG, Gallus A S, Hoek J A. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  NEJM. 2001;  344 619-625
• 31 Eriksson B I, Bauer K A, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  NEJM. 2001;  345 1298-1304
• 32 Bauer K A, Eriksson B I, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  NEJM. 2001;  345 1305-1310

Autoren